Rationale: Since their approval, there has been no real-world or randomized trial evidence
evaluating the effect of the antifibrotic medications pirfenidone and nintedanib on clinically …

Background Two antifibrotic drugs, pirfenidone and nintedanib, are licensed for the
treatment of patients with idiopathic pulmonary fibrosis (IPF). However, there is neither …

Rationale: In October 2014, the antifibrotic medications pirfenidone and nintedanib became
the first medications approved by the US Food and Drug Administration for use in patients …

We assessed safety and tolerability of treatment with pirfenidone (1602–2403 mg· day− 1)
and nintedanib (200–300 mg· day− 1) in patients with idiopathic pulmonary fibrosis (IPF) …

Background Idiopathic pulmonary fibrosis (IPF) is a form of chronic progressive fibrosing
interstitial lung disease of unknown origin. Recently, nintedanib and pirfenidone …

Rationale: Respiratory-related hospitalizations of patients with idiopathic pulmonary fibrosis
(IPF) are more frequent than those for acute IPF exacerbations and are associated with poor …

Background Real-life data on the use of pirfenidone and nintedanib to treat patients with
idiopathic pulmonary fibrosis (IPF) are still scarce. Methods We compared the efficacy of …

Objective: Provide information for pharmacists on idiopathic pulmonary fibrosis (IPF) and its
treatment. Study Selection and Data Extraction: All articles with data from randomized …

Idiopathic pulmonary fibrosis (IPF) is a progressive disease with a dismal prognosis. The
average life expectancy of untreated patients with IPF is only 3 to 4 years. Decline in forced …

Background Idiopathic pulmonary fibrosis (IPF) is a progressive fibrosing interstitial lung
disease associated with significant morbidity and mortality. Nintedanib and pirfenidone are …